PolyActiva presents positive clinical trial results at the 2022 American Glaucoma Society Annual Meeting – March 2022

PolyActiva announces positive Phase IIa results in glaucoma trial with low dose cohort.

PolyActiva successfully completes initial clinical trial with Latanoprost FA SR Ocular Implant delivering glaucoma treatment to patients over a six-month period.

PolyActiva appoints Tracy Valorie, ophthalmic industry expert and former Bausch + Lomb executive, to its Board of Directors.

PolyActiva completes recruitment in key Phase I glaucoma implant safety study. Six-month treatment period demonstrated.

PolyActiva commences its first Phase I clinical trial.

PolyActiva raises AUD$9.2M in Series B venture funding.